Ghayas Issa
@GhayasIssa
Followers
765
Following
109
Media
4
Statuses
153
Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.
Joined April 2017
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature .@MDAndersonNews.
30
72
254
RT @TheCancerLetter: Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNew….
0
5
0
RT @MDAndersonNews: "Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," s….
0
13
0
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
11
39
182
RT @break_cancer: We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to preven….
0
4
0
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD.
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration .@GhayasIssa @MDAndersonNews
4
12
53
Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval .
8
44
113
RT @lane_andy: How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::AB….
0
11
0
A pleasure to do this on differentiation syndrome with Eytan and Courtney. A thread 🧵 .
2
12
64
RT @NatRevDrugDisc: Menin inhibitors seek to debut as newest targeted therapy for leukaemia Find out how small mol….
0
4
0
RT @NitinJainMD: 👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL a….
0
16
0
Asciminib frontline!.
Presented at #ASCO24: . ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons.
0
5
22
Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :).
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24:.@MDAndersonNews.
1
0
3
RT @CD_AACR: Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published….
0
3
0
Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the “club”. Eytan and I have been brewing this trial for a while and it’s finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work).
1
2
17
0
0
5
RT @LeukDocJZ: Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in com….
0
11
0
RT @OncLive: Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML @GhayasIssa @MDAndersonNews @ASH_Hematology #ASH23 #ASH202….
0
1
0